X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES NATCO PHARMA JUBILANT LIFE SCIENCES/
NATCO PHARMA
 
P/E (TTM) x 12.5 13.1 95.7% View Chart
P/BV x 1.8 2.7 64.7% View Chart
Dividend Yield % 0.7 1.6 40.6%  

Financials

 JUBILANT LIFE SCIENCES   NATCO PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-18
NATCO PHARMA
Mar-18
JUBILANT LIFE SCIENCES/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0391,080 96.2%   
Low Rs600671 89.4%   
Sales per share (Unadj.) Rs482.6592.1 81.5%  
Earnings per share (Unadj.) Rs40.7188.4 21.6%  
Cash flow per share (Unadj.) Rs67.4206.3 32.6%  
Dividends per share (Unadj.) Rs3.008.25 36.4%  
Dividend yield (eoy) %0.40.9 38.9%  
Book value per share (Unadj.) Rs262.3833.6 31.5%  
Shares outstanding (eoy) m155.7936.90 422.2%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x1.71.5 114.8%   
Avg P/E ratio x20.14.6 433.0%  
P/CF ratio (eoy) x12.24.2 286.7%  
Price / Book Value ratio x3.11.1 297.4%  
Dividend payout %7.44.4 168.2%   
Avg Mkt Cap Rs m127,67032,311 395.1%   
No. of employees `0002.44.8 50.4%   
Total wages/salary Rs m15,5593,256 477.9%   
Avg. sales/employee Rs Th30,861.44,522.5 682.4%   
Avg. wages/employee Rs Th6,387.0674.0 947.7%   
Avg. net profit/employee Rs Th2,604.41,439.0 181.0%   
INCOME DATA
Net Sales Rs m75,17821,848 344.1%  
Other income Rs m400404 99.1%   
Total revenues Rs m75,57922,252 339.6%   
Gross profit Rs m15,1849,284 163.5%  
Depreciation Rs m4,151662 627.0%   
Interest Rs m2,843154 1,846.0%   
Profit before tax Rs m8,5918,872 96.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2471,920 117.0%   
Profit after tax Rs m6,3446,952 91.3%  
Gross profit margin %20.242.5 47.5%  
Effective tax rate %26.221.6 120.8%   
Net profit margin %8.431.8 26.5%  
BALANCE SHEET DATA
Current assets Rs m31,89821,307 149.7%   
Current liabilities Rs m20,0475,920 338.6%   
Net working cap to sales %15.870.4 22.4%  
Current ratio x1.63.6 44.2%  
Inventory Days Days6873 92.2%  
Debtors Days Days55107 51.5%  
Net fixed assets Rs m60,71514,986 405.1%   
Share capital Rs m156369 42.2%   
"Free" reserves Rs m40,71030,353 134.1%   
Net worth Rs m40,86530,760 132.9%   
Long term debt Rs m30,4780-   
Total assets Rs m96,17637,151 258.9%  
Interest coverage x4.058.6 6.9%   
Debt to equity ratio x0.70-  
Sales to assets ratio x0.80.6 132.9%   
Return on assets %9.619.1 49.9%  
Return on equity %15.522.6 68.7%  
Return on capital %16.029.3 54.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,40210,322 139.5%   
Fx outflow Rs m12,0442,978 404.4%   
Net fx Rs m2,3587,343 32.1%   
CASH FLOW
From Operations Rs m13,0324,636 281.1%  
From Investments Rs m-6,177-11,155 55.4%  
From Financial Activity Rs m-9,0116,509 -138.4%  
Net Cashflow Rs m-2,123-18 11,792.2%  

Share Holding

Indian Promoters % 45.6 52.0 87.6%  
Foreign collaborators % 3.5 1.5 238.1%  
Indian inst/Mut Fund % 8.7 7.8 111.0%  
FIIs % 21.2 16.6 127.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 26.0 81.2%  
Shareholders   23,815 25,395 93.8%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 318 Points Lower; Auto and Metal Stocks Witness Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day on a negative note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Jul 18, 2019 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS